- CA$15.82m
- CA$19.10m
- CA$0.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -966.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.14 | 0.11 | 0.27 | 0.67 | 0.03 | n/a | n/a | -51.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.
Directors
- Howard Verrico CHM
- Christopher Hopton CFO
- Geraldine Deliencourt-Godefroy CSO
- Alex Marazzi IND
- Jason Tian IND
- Last Annual
- October 31st, 2023
- Last Interim
- July 31st, 2024
- Incorporated
- October 19th, 2006
- Public Since
- July 10th, 2007
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 263,643,145
- Address
- c/o WeWork, 595 Burrard St., VANCOUVER, V7X 1L4
- Web
- https://www.sironabiochem.com/
- Phone
- +1 6046414466
- Auditors
- DeVisser Gray LLP
Upcoming Events for SBM
Q2 2025 Sirona Biochem Corp Earnings Release
Q3 2025 Sirona Biochem Corp Earnings Release
Similar to SBM
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the Sirona Biochem share price?
As of Today at 23:17 UTC, shares in Sirona Biochem are trading at CA$0.06. This share price information is delayed by 15 minutes.
How has the Sirona Biochem share price performed this year?
Shares in Sirona Biochem last closed at CA$0.06 and the price had moved by -29.41% over the past 365 days. In terms of relative price strength the Sirona Biochem share price has underperformed the Toronto Stock Exchange 300 Composite Index by -37.24% over the past year.
What are the analyst and broker recommendations for Sirona Biochem?
The overall consensus recommendation for Sirona Biochem is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sirona Biochem dividend yield?
Sirona Biochem does not currently pay a dividend.
Does Sirona Biochem pay a dividend?
Sirona Biochem does not currently pay a dividend.
When does Sirona Biochem next pay dividends?
Sirona Biochem does not currently pay a dividend.
How do I buy Sirona Biochem shares?
To buy shares in Sirona Biochem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sirona Biochem?
As of the previous close price of CA$0.06, shares in Sirona Biochem had a market capitalisation of CA$15.82m.
Where are Sirona Biochem shares listed?
Here are the trading details for Sirona Biochem:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: SBM
What kind of share is Sirona Biochem?
Based on an overall assessment of its quality, value and momentum Sirona Biochem is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sirona Biochem share price forecast for 2025?
The analyst consensus target price for shares in Sirona Biochem is CA$0.95. That is 1483.33% above the last closing price of CA$0.06.
Analysts covering Sirona Biochem currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Sirona Biochem share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sirona Biochem. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.72%.
As of the last closing price of CA$0.06, shares in Sirona Biochem were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sirona Biochem PE Ratio?
The Sirona Biochem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sirona Biochem?
Sirona Biochem's management team is headed by:
- Howard Verrico - CHM
- Christopher Hopton - CFO
- Geraldine Deliencourt-Godefroy - CSO
- Alex Marazzi - IND
- Jason Tian - IND